×
0 0 0 0 0.0108333333333333 0.000333333333333385 0.00216666666666671 0.00333333333333338
Stockreport

SAGE says no M&A discussions are taking place; shares ease 4% premarket [Seeking Alpha]

SAGE THERAPEUTICS (SAGE)  More Company Research Source: Seeking Alpha
Last sage therapeutics earnings: 2/22 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sagerx.com/investor-relations
PDF In a statement , SAGE Therapeutics (NASDAQ: SAGE ) says CEO Jeff Jonas acknowledged industry interest in the MDD data related to SAGE-217 during an interview but did not imply that the firm was talking with potential acquirers. The company adds that it will make no further comments on the matter or on future speculation on M&A activities. Shares are down   premarket on light volume. Now read: 2 Biotechs That Might Help With Investor Depression » [Read more]

IMPACT SNAPSHOT EVENT TIME: SAGE
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS